NASDAQ:SGYP - Synergy Pharmaceuticals Stock Price, Price Target & More

Synergy Pharmaceuticals trades on the NASDAQ under the ticker symbol "SGYP."

Synergy Pharmaceuticals Inc (NASDAQ:SGYP) announced its quarterly earnings results on Thursday, May, 10th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.16) by $0.01. The biopharmaceutical company earned $8.59 million during the quarter, compared to analyst estimates of $11.18 million. Synergy Pharmaceuticals had a negative return on equity of 652.66% and a negative net margin of 773.82%. Synergy Pharmaceuticals's quarterly revenue was up 776.5% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.30) earnings per share. View Synergy Pharmaceuticals' Earnings History.

8 brokers have issued 1-year price objectives for Synergy Pharmaceuticals' stock. Their predictions range from $2.50 to $15.00. On average, they anticipate Synergy Pharmaceuticals' share price to reach $8.8125 in the next year. This suggests a possible upside of 363.8% from the stock's current price. View Analyst Ratings for Synergy Pharmaceuticals.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Synergy Pharmaceuticals in the last year. There are currently 4 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Synergy Pharmaceuticals saw a drop in short interest in the month of June. As of June 29th, there was short interest totalling 54,868,105 shares, a drop of 12.8% from the June 15th total of 62,939,216 shares. Based on an average daily trading volume, of 3,251,186 shares, the short-interest ratio is currently 16.9 days. Approximately 22.3% of the shares of the stock are sold short. View Synergy Pharmaceuticals' Current Options Chain.

Some companies that are related to Synergy Pharmaceuticals include PTC Therapeutics (PTCT), Cambrex (CBM), Mallinckrodt (MNK), AnaptysBio (ANAB), Aimmune Therapeutics (AIMT), Mirati Therapeutics (MRTX), G1 Therapeutics (GTHX), IMMURON Ltd/S (IMRN), ARMO Biosciences (ARMO), Pacira Pharmaceuticals (PCRX), Corcept Therapeutics (CORT), Innoviva (INVA), Biohaven Pharmaceutical (BHVN), TherapeuticsMD (TXMD) and Theravance Biopharma (TBPH).

News headlines about SGYP stock have trended somewhat positive recently, Accern reports. The research firm rates the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Synergy Pharmaceuticals earned a media sentiment score of 0.13 on Accern's scale. They also assigned media coverage about the biopharmaceutical company an impact score of 44.93 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

Shares of SGYP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of SGYP stock can currently be purchased for approximately $1.90.

Synergy Pharmaceuticals has a market capitalization of $468.81 million and generates $16.82 million in revenue each year. The biopharmaceutical company earns $-224,330,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis. Synergy Pharmaceuticals employs 313 workers across the globe.

Synergy Pharmaceuticals' mailing address is 420 LEXINGTON AVENUE SUITE 2012, NEW YORK NY, 10170. The biopharmaceutical company can be reached via phone at 212-297-0020 or via email at [email protected]